|
WO2020117987A1
|
|
Compositions and methods for the treatment of liver disorders
|
|
WO2020117962A1
|
|
Compositions for the treatment of fibrosis and inflammation
|
|
AU2019238090A1
|
|
Crystalline forms and methods of producing crystalline forms of a compound
|
|
US2020179412A1
|
|
Compositions for the treatment of fibrosis
|
|
WO2018094265A2
|
|
Method of treating glycogen storage disease
|
|
WO2018053036A1
|
|
Method of reducing thyroid-associated side effects
|
|
KR20190039027A
|
|
Use of thyroid beta-agonists
|
|
KR20190017748A
|
|
Use of thyroid beta-agonists
|
|
AU2016326397A1
|
|
Conjoint therapies with inhibitors of glucose production
|
